surmount-1 tirzepatide 15 mg weight loss percent Relationship of early rapid to efficacy and safety of and semaglutide for obesity: SURMOUNT-5 post hoc analysis Semaglutide vs. Tirzepatide for Obesity

GLP-1 receptor agonists like dulaglutide or exenatide overlap directly with semaglutide's mechanism

ColonBroom GLP-1 potential side effects: Digestive sensitivity : In the first week, some users experience loose stools, mild bloating, or upset stomach

The Dosage Dilemma: Stepping Down vs

So vi thuc GLP-1 dng vin trc nh Rybelsus hoc Wegovy vi hot cht semaglutide, Foundayo c thit k d s dng hn trong i sng hng ngy

This dual mechanism enhances insulin secretion when blood glucose levels are elevated, suppresses glucagon release, slows gastric emptying, and reduces appetite, thereby improving glycaemic control and often leading to significant weight loss

*In a 72-week study of adults without diabetes (SURMOUNT-1), average weight loss was 15.0% (34 lbs) for 5mg, 19.5% (44 lbs) for 10mg, 20.9% (48 lbs) for 15mg, and 3.1% (7 lbs) for placebo